PHAT News and Press, Phathom Pharmaceuticals Inc. From 05/10/22

U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H. pylori infection in adults Up to $260 million revenue...

New Jersey-based pharmaceutical company, Phathom Pharmaceuticals (NASDAQ:PHAT), announced that the U.S. Food and Drug Administration (FDA) approved its antibacterial drugs, Voquezna Triple Pak and Voquezna Dual Pak, for the treatment of Helicobacter pylori infection in adults. Voque...

Phathom Pharmaceuticals (NASDAQ:PHAT) announces a revenue interest financing of up to $260M in non-dilutive capital. The agreement provides for an upfront $100M cash payment and an additional $160M cash payment upon FDA approval of vonoprazan for treatment of EE. Sagard Healthcare Partne...

Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE) Provides capital for launch of vonoprazan in H. pylori and EE, if approved, in addition to Phase 3 program in non-erosive reflux diseas...

VOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple therapy in the overall patient population of the pivotal Phase 3 trial 1 VOQUEZN...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors...

FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team ...

Phathom Pharmaceuticals (NASDAQ:PHAT) stated Tuesday that it has appointed Molly Henderson as the company's new chief financial and business officer, effective Apr. 5, 2022. Henderson has most recently served as CFO of UroGen Pharma (URGN), and previously at Advaxis (OTC:ADXS)....

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson t...